Noémie Jourde-Chiche

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2067067/publications.pdf

Version: 2024-02-01

80 papers 3,514 citations

201674 27 h-index 56 g-index

96 all docs 96 docs citations

96 times ranked

4849 citing authors

#	Article	IF	CITATIONS
1	Modular Transcriptional Repertoire Analyses of Adults With Systemic Lupus Erythematosus Reveal Distinct Type I and Type II Interferon Signatures. Arthritis and Rheumatology, 2014, 66, 1583-1595.	5.6	302
2	Endothelium structure and function in kidney health and disease. Nature Reviews Nephrology, 2019, 15, 87-108.	9.6	292
3	The Cardiovascular Effect of the Uremic Solute Indole-3 Acetic Acid. Journal of the American Society of Nephrology: JASN, 2015, 26, 876-887.	6.1	239
4	Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Annals of the Rheumatic Diseases, 2018, 77, 1143-1149.	0.9	219
5	Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney International, 2013, 84, 733-744.	5.2	205
6	Vascular Incompetence in Dialysis Patientsâ€"Proteinâ€Bound Uremic Toxins and Endothelial Dysfunction. Seminars in Dialysis, 2011, 24, 327-337.	1.3	158
7	Mortality Associated With Systemic Lupus Erythematosus in France Assessed by Multipleâ€Causeâ€ofâ€Death Analysis. Arthritis and Rheumatology, 2014, 66, 2503-2511.	5.6	152
8	PROGRESS IN UREMIC TOXIN RESEARCH: Proteinâ€Bound Toxinsâ€"Update 2009. Seminars in Dialysis, 2009, 22, 334-339.	1.3	139
9	The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fiftyâ€Seven Patients. Arthritis and Rheumatology, 2015, 67, 527-534.	5.6	136
10	Does Uremia Cause Vascular Dysfunction. Kidney and Blood Pressure Research, 2011, 34, 284-290.	2.0	122
11	Characteristics and Management of IgA Vasculitis (Henochâ€Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. Arthritis and Rheumatology, 2017, 69, 1862-1870.	5.6	117
12	Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease. Kidney International, 2018, 93, 986-999.	5.2	79
13	Atypical and secondary hemolytic uremic syndromes have a distinct presentation andÂnoÂcommon genetic risk factors. Kidney International, 2019, 95, 1443-1452.	5.2	74
14	Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney International, 2019, 95, 666-679.	5.2	68
15	Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. Medicine (United States), 2016, 95, e3748.	1.0	64
16	Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2281-2286.	2.3	63
17	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 2018, 17, 1153-1168.	5.8	62
18	Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 431-441.	4.5	54

#	Article	IF	Citations
19	An interactive web application for the dissemination of human systems immunology data. Journal of Translational Medicine, 2015, 13, 196.	4.4	49
20	Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor-kappa B signaling pathway in human endothelial cells. Archives of Toxicology, 2019, 93, 121-136.	4.2	43
21	Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort. CKJ: Clinical Kidney Journal, 2020, 13, 878-888.	2.9	43
22	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Frontiers in Immunology, 2018, 9, 2260.	4.8	42
23	Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrology Dialysis Transplantation, 2021, 36, 1664-1674.	0.7	41
24	Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. British Journal of Clinical Pharmacology, 2019, 85, 403-412.	2.4	39
25	Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. Journal of Autoimmunity, 2015, 65, 49-55.	6.5	34
26	Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. Rheumatology, 2017, 56, kew439.	1.9	34
27	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
28	Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease. Toxins, 2019, 11, 578.	3.4	32
29	Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. Nature Communications, 2021, 12, 4385.	12.8	29
30	Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation. Journal of Immunology Research, 2019, 2019, 1-14.	2.2	27
31	Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges. Journal of the American Society of Nephrology: JASN, 2022, 33, 628-637.	6.1	24
32	Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 1420-1427.	0.9	24
33	Gastrointestinal involvement in adult IgA vasculitis (Henoch-Schönlein purpura): updated picture from a French multicentre and retrospective series of 260 cases. Rheumatology, 2020, 59, 3050-3057.	1.9	23
34	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. Seminars in Arthritis and Rheumatism, 2021, 51, 339-346.	3.4	22
35	Disease Mechanisms in Rheumatologyâ€"Tools and Pathways: Current Perspectives on Systems Immunology Approaches to Rheumatic Diseases. Arthritis and Rheumatism, 2013, 65, 1407-1417.	6.7	21
36	Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling. Journal of the American Society of Nephrology: JASN, 2018, 29, 906-918.	6.1	21

#	Article	lF	Citations
37	Original Approach for Automated Quantification of Antinuclear Autoantibodies by Indirect Immunofluorescence. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	20
38	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. Arthritis Research and Therapy, 2020, 22, 223.	3.5	18
39	Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. JAMA Network Open, 2022, 5, e2220925.	5.9	18
40	MYH9-related disorders display heterogeneous kidney involvement and outcome. CKJ: Clinical Kidney Journal, 2019, 12, 494-502.	2.9	16
41	<i>Bartonella and Coxiella</i> infections presenting as systemic vasculitis: case series and review of literature. Rheumatology, 2022, 61, 2609-2618.	1.9	15
42	Autoantibodies Targeting Ficolinâ€2 in Systemic Lupus Erythematosus Patients With Active Nephritis. Arthritis Care and Research, 2018, 70, 1263-1268.	3.4	14
43	Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 964-972.	4.5	13
44	Apheresis to treat systemic vasculitis. Joint Bone Spine, 2018, 85, 177-183.	1.6	12
45	Accumulation of protein-bound uremic toxins: the kidney remains the leading culprit in the gut-liver-kidney axis. Kidney International, 2020, 97, 1102-1104.	5. 2	12
46	Spike and neutralizing antibodies response to COVID-19 vaccination in haemodialysis patients. CKJ: Clinical Kidney Journal, 2021, 14, 2239-2245.	2.9	12
47	Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy. Kidney International, 2022, 102, 904-916.	5. 2	12
48	Association between anti-C1q antibodies and glomerular tuft necrosis in lupus nephritis. Clinical Nephrology, 2012, 77, 211-218.	0.7	11
49	Paradoxical association between blood modular interferon signatures and quality of life in patients with systemic lupus erythematosus. Rheumatology, 2020, 59, 1975-1983.	1.9	10
50	Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy. BMC Nephrology, 2020, 21, 260.	1.8	10
51	Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. Journal of Clinical Medicine, 2021, 10, 1690.	2.4	10
52	Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients. CKJ: Clinical Kidney Journal, 2022, 15, 1747-1754.	2.9	10
53	Impact of aging on phenotype and prognosis in IgA vasculitis. Rheumatology, 2021, 60, 4245-4251.	1.9	9
54	Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection. Case Reports in Transplantation, 2017, 2017, 1-7.	0.3	8

#	Article	IF	CITATIONS
55	Hemodialysis vascular graft as a focus of persistent Q fever. Infection, 2018, 46, 881-884.	4.7	8
56	Serum GlycA Level Is Elevated in Active Systemic Lupus Erythematosus and Correlates to Disease Activity and Lupus Nephritis Severity. Journal of Clinical Medicine, 2020, 9, 970.	2.4	8
57	Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes. Kidney International Reports, 2021, 6, 746-754.	0.8	8
58	Unsupervised clustering analysis of data from an online community to identify lupus patient profiles with regards to treatment preferences. Lupus, 2021, 30, 1837-1843.	1.6	8
59	Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1665-1675.	4.5	8
60	Introducing a New Dimension to Molecular Disease Classifications. Trends in Molecular Medicine, 2016, 22, 451-453.	6.7	7
61	Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology, 2020, 59, 2970-2975.	1.9	7
62	IgA Vasculitis With Underlying Liver Cirrhosis: A French Nationwide Case Series of 20 Patients. Journal of Rheumatology, 2021, 48, 735-740.	2.0	7
63	Clinical phenotype and cytokine profile of adult IgA vasculitis with joint involvement. Clinical Rheumatology, 2022, 41, 1483-1491.	2.2	6
64	Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys. Kidney International Reports, 2021, 6, 2134-2143.	0.8	4
65	Acute pancreatitis as a cause of mortality in pediatric systemic lupus erythematosus: Results of a multiple cause-of-death analysis in France. Seminars in Arthritis and Rheumatism, 2016, 46, e6-e7.	3.4	3
66	Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients. Journal of Clinical Medicine, 2019, 8, 298.	2.4	3
67	Should the Biopsychosocial Model Be Considered in Systemic Autoimmune Diseases? Comment on the Article by Posada et al. Arthritis and Rheumatology, 2021, 73, 717-718.	5.6	3
68	Diagnostic performance of pulmonary ultrasonography and a clinical score for the evaluation of fluid overload in haemodialysis patients. Nephrologie Et Therapeutique, 2021, 17, 42-49.	0.5	3
69	Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis. BMC Nephrology, 2022, 23, 67.	1.8	3
70	From BLISS to ILLUMINATE studies: "Blys repetita placentâ€?: TableÂ1. Annals of the Rheumatic Diseases, 2016, 75, e10-e10.	0.9	2
71	Sera From Patients With Minimal Change Disease Increase Endothelial Permeability to Sodium. Kidney International Reports, 2020, 5, 1071-1075.	0.8	2
72	Endothelial-Specific Deletion of CD146 Protects Against Experimental Glomerulonephritis in Mice. Hypertension, 2021, 77, 1260-1272.	2.7	2

#	Article	IF	CITATIONS
73	Kidney biopsy in very elderly patients: indications, therapeutic impact and complications. BMC Nephrology, 2021, 22, 362.	1.8	2
74	French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis. Presse Medicale, 2022, 51, 104107.	1.9	2
75	Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19. Scientific Reports, 2022, 12, .	3.3	2
76	AphérÃ"ses dans le traitement des vascularites systémiques. Revue Du Rhumatisme Monographies, 2017, 84, 270-275.	0.0	1
77	First phenotypic description of a female patient with c.610 T > C variant of GLA: a renal-predominant presentation of Fabry disease. BMC Medical Genetics, 2020, 21, 137.	2.1	1
78	Reply to â€~Kidney involvement in hereditary transthyretin amyloidosis: is there a role for cystatin C?'. CKJ: Clinical Kidney Journal, 0, , .	2.9	1
79	PO360URINARY PEPTIDOMIC ANALYSIS IN PROLIFERATIVE VERSUS NON-PROLIFERATIVE LUPUS NEPHRITIS : RESULTS OF THE PEPTIDU-LUP STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	O
80	RÃ1e du complément dans la néphropathie lupique et la néphropathie du syndrome des anti-phospholipides. La Presse Médicale Formation, 2022, 3, 156-156.	0.1	0